Brought to you by 
Biohaven in-licenses CNS compounds BHV3000, BHV3500 from BMS; later restructures deal
Apr 2017
Executive Summary
Biohaven Pharmaceuticals Holding Co. Ltd. licensed exclusive, worldwide development and commercialization rights to two of Bristol-Myers Squibb Co.'s CNS development compounds (rimegepant (BHV3000) and BHV3500) and other BMS intellectual property surrounding calcitonin gene-related peptide (CGRP) receptors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Reverse Licensing
- Includes Royalty or Profit Split Information
- Includes Equity
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biohaven in-licenses CNS compounds BHV3000, BHV3500 from BMS; later restructures deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice